Elanco Leads in Screwworm Treatment as Rivals Target Prevention

Elanco’s April 2026 emergency authorizations for Negasunt Powder and Tanidil give the company a meaningful lead in the U.S. response to New World screwworm, but the advantage is more specialized than sweeping.

The lead appears strongest where the outbreak response is clinical, urgent and government-directed: treating open wounds, limiting larval spread and supplying products through the federal biosecurity apparatus. It is weaker where the market shifts toward herd-level prevention, residual protection and lower-labor administration.

That distinction matters. Screwworm is not a conventional parasite problem. New World screwworm larvae feed on living tissue, can spread rapidly through untreated wounds and pose a direct threat to livestock productivity and mortality. Modeling cited in the brief estimates that even a localized outbreak in Texas could create a $1.8 billion economic loss. In that setting, the first products embedded into the federal response system gain strategic value beyond normal product sales.

Elanco has that position today. The question is how long it lasts.

Elanco’s advantage comes less from shelf space than from being written into the emergency response playbook.

Negasunt and Tanidil entered the U.S. market through two different emergency pathways. Negasunt received an FDA Emergency Use Authorization. Tanidil received an EPA Section 18 emergency exemption, effective through April 27, 2029.

That matters because these are not ordinary commercial launches.

According to the brief, Negasunt and Tanidil are distributed through USDA APHIS and the National Veterinary Stockpile, not through standard retail channels. This shifts competition away from veterinarian preference and distributor economics toward government procurement, emergency logistics and official containment protocols.

For Elanco, that creates a modest but real moat. Once a product becomes part of the official response architecture, competitors need more than a similar label. They need a comparable regulatory authorization, government acceptance, available supply and operational fit within state and federal outbreak protocols.

That is not impossible. But it is slower than conventional fast-following.

Negasunt appears better suited to active wound management than systemic competitors.

The clearest product-level advantage sits in Negasunt’s formulation. It combines coumaphos, propoxur and sulfanilamide. The brief identifies sulfanilamide as a differentiator because it adds an antimicrobial component to the insecticidal effect.

That is commercially relevant because screwworm infestations are not clean parasitic events. The larvae damage tissue, deepen wounds and create conditions for secondary infection. A product that treats the wound environment, not only the parasite, has a more defensible role in active cases.

The FDA’s Freedom of Information summary, as cited in the brief, also appears supportive. Some studies lacked the parameters usually required for full approval, but the product reportedly demonstrated 100% efficacy in preventing larval establishment and treating existing infestations.

That does not make the emergency authorization permanent. It does suggest Elanco has a data package that could support a path toward broader or more durable authorization if the threat persists.

The same features that make the products useful in severe cases limit their scalability.

Elanco’s lead is not frictionless.

Negasunt and Tanidil rely on organophosphate and carbamate chemistry. The brief notes stringent PPE requirements, including chemical-resistant gloves, coveralls and NIOSH-approved respirators. Applicators also face limits on daily treatment volume: no more than three large wounds or 30 small superficial wounds per person per day.

Those constraints are manageable in targeted treatment. They become a bottleneck in a larger outbreak.

This is where fast followers have room. Large ranches and feedlots do not want repeated animal handling, worker exposure limits and reapplication every two to three days if an injectable or pour-on product can provide residual protection. In a mass-response environment, labor intensity becomes a strategic weakness.

Tanidil adds a supply-chain vulnerability. The brief states that it is manufactured in Brazil and requires a 90-to-100-day importation and relabeling timeline.

That delay is not trivial in a seasonal pest emergency. A domestic manufacturer with a credible topical or systemic alternative could exploit that gap, especially if APHIS decides supply redundancy matters more than product purity.

Elanco leads in wound treatment. Competitors look better positioned for prevention and residual protection.

Zoetis and Merck do not need to displace Elanco product-for-product to reduce its opportunity.

Zoetis secured conditional approval for Dectomax-CA1, a doramectin injectable, in late 2025. Its strategic advantage is residual protection. The brief cites 21 days of protection against reinfestation, which is operationally attractive for grazing systems where animals cannot be inspected every 48 hours.

Merck’s Exzolt Cattle-CA1 offers a different angle. Its fluralaner pour-on is labeled for both New World screwworm and cattle fever tick, which gives it relevance across two border-related animal health risks. But the brief notes a major commercial constraint: a 98-day withdrawal period. That is a substantial disadvantage in fed cattle.

Elanco’s 28-day withdrawal period therefore matters. In a tight beef market, time away from the slaughter channel carries real economic cost. A shorter withdrawal period helps defend Elanco’s relevance in animals closer to market.

Still, the competitive pattern is clear. Elanco owns the acute wound-treatment niche. Zoetis and Merck are better aligned with prevention, residual coverage and reduced handling. Those segments may expand if the outbreak moves from isolated cases to broader regional risk management.

The authorizations support Elanco’s innovation story, but probably do not reset the company’s valuation on their own.

The financial contribution is likely attractive because the products already exist in other markets. The brief frames Negasunt and Tanidil as low-cost, high-leverage additions, with limited incremental R&D relative to new drug development.

That matters for Elanco because management has raised its 2026 innovation revenue target to $1.15 billion, from an earlier $1.1 billion projection. The company also reported $4.715 billion of 2025 revenue and guided to $4.95 billion to $5.02 billion for 2026, according to the brief.

Against that base, screwworm countermeasures are unlikely to be company-defining unless the outbreak becomes materially larger. The more important value may be strategic. These products reinforce Elanco’s position as a ready supplier to regulators and livestock producers during a biosecurity event.

That can matter later, especially in animal health markets where trust, field access and regulator familiarity shape adoption.

Sterile insect technology could shrink the addressable market for all chemical treatments.

The most important erosion risk may not come from Zoetis, Merck or Boehringer Ingelheim.

It may come from sterile insect technology.

The brief points to USDA ARS work on NovoFly, a genetically engineered male-only sterile screwworm approach. Traditional sterile insect technique releases both sterile males and females, while a male-only system could improve production efficiency by eliminating an expensive biological inefficiency.

If that system scales, the commercial market for chemical treatment could narrow. Chemical products remain essential in focal outbreaks and active wounds. But if sterile insect releases suppress the population effectively, demand for repeated prophylaxis and treatment could fall.

That is a five-to-10-year issue, not an immediate displacement. In the near term, limited sterile insect capacity likely protects the need for chemical countermeasures. Over time, however, it caps the durability of any product-based moat.

Elanco has a defensible lead for 2026 to 2028, but not a permanent franchise.

Elanco’s lead appears real because it sits at the intersection of regulatory timing, clinical utility and federal distribution. Fast followers can compete around it, but they are unlikely to erase it quickly.

The company’s strongest position is active wound treatment under government-directed outbreak response. Negasunt’s antimicrobial component, multi-species authorization and National Veterinary Stockpile channel give it a role that systemic products do not fully replicate.

The weaker position is herd-level prevention. Zoetis, Merck and others can pressure Elanco where residual protection, fewer handling events and simpler administration matter more than wound-level treatment.

The practical conclusion is that Elanco has built a specialized moat, not a broad monopoly. It likely has a meaningful lead through the early emergency phase. Its durability depends on whether the U.S. response remains focused on focal treatment and stockpile deployment, or shifts toward mass prevention, domestic supply redundancy and eventually sterile insect suppression.